公开(公告)号：EP3274334A1

公开(公告)日：2018-01-31

申请号：EP16713808.0

申请日：2016-03-24

申请人： BASF SE

发明人： KOENEMANN, Martin ,  WAGENBLAST, Gerhard ,  IVANOVICI, Sorin ,  MATTERN, Gabriele ,  MITGUDE, Martina ,  WEBER, Gerd

IPC分类号： C07D221/18 ,  C09K11/06 ,  H01L31/048 ,  H01L31/055 ,  H01L33/50 ,  C07D241/00 ,  H01L51/00

CPC分类号： C07D493/06 ,  C07D491/06 ,  C07D491/16 ,  C07D495/06 ,  C09B5/62 ,  C09B57/08 ,  C09K11/06 ,  C09K2211/1029 ,  C09K2211/1033 ,  C09K2211/1037 ,  C09K2211/1044 ,  C09K2211/1048 ,  C09K2211/1051 ,  C09K2211/1088 ,  C09K2211/1092 ,  H01L33/502 ,  H01L51/5281 ,  H05K999/99 ,  Y02E10/52

摘要： The present invention relates to cyanated compounds of the formula (I) wherein at least one of the radicals R2, R3, R4 and R5 is CN, and the remaining radicals are selected from hydrogen, chlorine and bromine; X is O, S, SO or SO2; m is 0, 1, 2, 3 or 4; R1 is selected from bromine, chlorine, cyano, —NRaRb, C1-C24-alkyl, C1-C24-haloalkyl, C1-C24-alkoxy, C1-C24-haloalkoxy, C3-C24-cycloalkyl, heterocycloalkyl, heteroaryl, C6-C24-aryl, C6-C24-aryloxy, C6-C24-aryl-C1-C10-alkylene, etc.; A is a diradical selected from diradicals of the general formulae (A.1), (A.2), (A.3), and (A.4) wherein R6, (R7)n, (R8)o and (R9)p are as defined in the claims and in the description. The invention further relates to color converters comprising at least one polymer as a matrix material and at least one cyanated compound of formula (I) or mixtures thereof as a fluorescent dye, to the use of the color converters and to lighting devices comprising at least one LED and at least one color converter.

公开(公告)号：EP3072887A1

公开(公告)日：2016-09-28

申请号：EP16162116.4

申请日：2016-03-24

申请人： BASF SE

发明人： KOENEMANN, Martin ,  WAGENBLAST, Gerhard ,  IVANOVICI, Sorin ,  MITGUDE, Martina ,  CARVALHO, Mary-Ambre

IPC分类号： C07D221/18 ,  C09K11/06 ,  H01L31/048 ,  H01L31/055 ,  H01L33/50 ,  C07D241/00 ,  H01L51/00 ,  H05B33/14

CPC分类号： C09K11/06 ,  C07D487/06 ,  C09K2211/1007 ,  C09K2211/1044 ,  H01L31/055 ,  H01L33/502 ,  H01L51/0053 ,  H01L51/0054 ,  H01L51/5281 ,  H05B33/14 ,  Y02B20/181 ,  Y02E10/52 ,  Y02E10/549

摘要： The present invention relates to N,N'-bis(2,6-diisopropylphenyl)-1,7-di(2,6-diphenyl-phenoxy)perylen-3,4;9,10-tetracarboximide, N,N'-bis(2,6-diisopropylphenyl)-1,6-di(2,6-diphenylphenoxy)perylen-3,4;9,10-tetracarboximide, to a method for preparation and use thereof. In particular, the present invention relates to the use of said compound(s) in color converters for improving the luminous efficacy of white-light emitting diodes. The present invention also relates to the use of these color converters and to lighting devices comprising at least one LED or OLED and at least one color converter.

摘要翻译： 本发明涉及N，N'-双（2,6-二异丙基苯基）-1,7-二（2,6-二苯基 - 苯氧基）苝基-3,4; 9,10-四甲酰亚胺，N， 双（2,6-二异丙基苯基）-1,6-二（2,6-二苯基苯氧基）苝基-3,4; 9,10-四羧酰亚胺的制备方法。 特别地，本发明涉及所述化合物在颜色转换器中用于提高白光发光二极管发光效率的用途。 本发明还涉及这些颜色转换器和包括至少一个LED或OLED和至少一个颜色转换器的照明装置的使用。

公开(公告)号：EP2146994B1

公开(公告)日：2015-07-01

申请号：EP08787944.1

申请日：2008-04-11

申请人： NOVEXEL

发明人： LAMPILAS, Maxime ,  ROWLANDS, David, Alun ,  KEBSI, Adel ,  LEDOUSSAL, Benoît ,  PIERRES, Camille

IPC分类号： C07D471/18 ,  A61K31/529 ,  A61P31/04 ,  C07D471/08 ,  C07D211/56 ,  C07D241/00 ,  A61P31/00

CPC分类号： C07D471/18

公开(公告)号：EP0854140B1

公开(公告)日：2013-11-06

申请号：EP97121932.4

申请日：1997-12-12

申请人： Sanofi-Aventis Deutschland GmbH ,  Genentech, Inc.

发明人： Wehner, Volkmar, Dr. ,  Stilz, Hans Ulrich, Dr. ,  Peyman, Anuschirwan, Dr. ,  Knolle, Jochen, Dr. ,  Ruxer, Jean-Marie, Dr. ,  Carniato, Denis, Dr. ,  Lefrancois, Jean-Michel ,  Gadek, Thomas Richard, Dr. ,  McDowell, Robert, Dr.

IPC分类号： C07D217/24 ,  C07D235/16 ,  C07D487/04 ,  A61K31/415 ,  A61K31/44 ,  A61K31/47 ,  C07D241/00 ,  C07D233/00 ,  C07D213/00 ,  C07D249/00

CPC分类号： C07D487/04

公开(公告)号：EP1824856B1

公开(公告)日：2013-10-23

申请号：EP05819148.7

申请日：2005-12-08

申请人： Janssen Pharmaceutica NV

发明人： FREYNE, Eddy Jean E., Janssen Pharmaceutica N.V. ,  WILLEMS, Marc, Janssen Pharmaceutica N.V. ,  EMBRECHTS, Werner C. J., Janssen Pharmaceutica N.V ,  VAN EMELEN, Kristof, Janssen Pharmaceutica N.V. ,  VAN BRANDT, Sven F. A., Janssen Pharmaceutica N.V. ,  ROMBOUTS, Frederik J R, Janssen Pharmaceutica N.V.

IPC分类号： C07D487/08 ,  C07D487/22 ,  C07D498/18 ,  A61K31/505 ,  A61P35/00 ,  C07D259/00 ,  C07D239/00 ,  C07D241/00 ,  C07D209/00 ,  C07D273/00 ,  C07D221/00

CPC分类号： C07D487/18 ,  C07D487/08 ,  C07D487/22 ,  C07D498/08 ,  C07D498/18

公开(公告)号：EP1796669B1

公开(公告)日：2010-09-22

申请号：EP05802868.9

申请日：2005-09-27

申请人： Merck Sharp & Dohme Corp.

发明人： COX, Jason, M. ,  EDMONDSON, Scott, D. ,  HARPER, Bart ,  WEBER, Ann, E.

IPC分类号： A61K31/445 ,  A61K31/495 ,  A61K31/50 ,  A61K31/505 ,  A61K31/525 ,  C07D237/26 ,  C07D239/00 ,  C07D239/70 ,  C07D239/72 ,  C07D241/00 ,  C07D241/36 ,  C07D401/04 ,  C07D471/04 ,  C07D491/04 ,  C07D487/00

CPC分类号： C07D401/04 ,  C07D471/04 ,  C07D487/04

摘要： The present invention is directed to novel substituted aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DPP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

公开(公告)号：EP1796669A4

公开(公告)日：2009-08-19

申请号：EP05802868

申请日：2005-09-27

申请人： MERCK & CO INC

发明人： COX JASON M ,  EDMONDSON SCOTT D ,  HARPER BART ,  WEBER ANN E

IPC分类号： A61K31/445 ,  A61K31/495 ,  A61K31/50 ,  A61K31/505 ,  A61K31/525 ,  C07D237/26 ,  C07D239/00 ,  C07D239/70 ,  C07D239/72 ,  C07D241/00 ,  C07D241/36 ,  C07D401/04 ,  C07D471/04 ,  C07D487/00 ,  C07D491/04

CPC分类号： C07D401/04 ,  C07D471/04 ,  C07D487/04

公开(公告)号：EP1797073A2

公开(公告)日：2007-06-20

申请号：EP05795448.9

申请日：2005-09-09

申请人： Merck & Co., Inc.

发明人： BELL, Ian, M. ,  THEBERGE, Cory, R. ,  STUMP, Craig, A. ,  ZHANG, Xufang ,  GALLICCHIO, Steven, N. ,  ZARTMAN, C., Blair

IPC分类号： C07D403/02 ,  C07D221/02 ,  C07D401/00 ,  C07D239/00 ,  C07D241/00 ,  A61K31/4965 ,  A61K31/44 ,  A61K31/517

CPC分类号： C07D401/14 ,  C07D403/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D519/00 ,  Y02P20/582

摘要： The present invention is directed to compounds of Formula (I): (where variables A1, A2, B, J, K, m, n, R4, R5a, R5b and R5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

公开(公告)号：EP1789410A1

公开(公告)日：2007-05-30

申请号：EP05789636.7

申请日：2005-09-16

申请人： GLAXO GROUP LIMITED

发明人： BRUTON, Gordon GlaxoSmithKline ,  JOHNSTONE, Vicky GlaxoSmithKline ,  ORLEK, Barry Sidney GlaxoSmithKline

IPC分类号： C07D401/04 ,  C07D413/14 ,  C07D401/14 ,  A61K31/4545 ,  A61P25/00 ,  C07D241/00 ,  C07D211/00 ,  C07D213/00 ,  C07D271/00

CPC分类号： C07D413/14 ,  C07D401/14

摘要： The present invention relates to novel methylene dipiperidine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

摘要翻译： 本发明涉及具有药理学活性的新亚甲基二哌啶衍生物，其制备方法，含有它们的组合物以及它们在治疗神经和精神疾病中的用途。

公开(公告)号：EP1660184A2

公开(公告)日：2006-05-31

申请号：EP04777129.0

申请日：2004-06-25

申请人： Merck & Co., Inc.

发明人： DANKULICH, William, P. ,  KAUFMAN, Mildred, L. ,  MEISSNER, Robert, S. ,  MITCHELL, Helen, J.

IPC分类号： A61P19/00 ,  A61K31/56 ,  A61K31/58 ,  C07D221/18 ,  C07D221/22 ,  C07D239/02 ,  C07D241/00

CPC分类号： C07J73/005

摘要： Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), cancer cachexia, Alzheimer’s disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.